Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg".
Press Release Feb 18 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Bosentan tablets for oral suspension, which are indicated for treating Pulmonary Arterial Hypertension in children. The approval allows Zydus to manufacture the tablets at its facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 17 2026
- Press Release Feb 14 2026
- Press Release 10-02-2026 NewspaperPublication10022026
- Press Release Feb 09 2026
- Press Release Feb 06 2026
Later from Zydus Lifesciences
- Press Release Feb 19 2026
- Press Release Feb 25 2026
- Press Release Feb 27 2026
- Press Release Feb 28 2026
- Press Release Mar 12 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences